Latest ARCH VENTURE CORP Stock Portfolio

$677Million | No. of Holdings #10

ARCH VENTURE CORP Performance

2026 Q1+5.51%

YTD+5.51%

2025+73.87%

About ARCH VENTURE CORP and 13F Hedge Fund Stock Holdings

On 2026-05-15, the fund reported it's updated stock portfolio. In the 13F Holdings report, ARCH Venture Management, LLC reported an equity portfolio of $677.1 Millions as of 31 Mar, 2026. <br><br> The top stock holdings of ARCH Venture Management, LLC are , , VIR. The fund has invested 18.2% of it's portfolio in MAZE THERAPEUTICS INC and 17.2% of portfolio in RAPPORT THERAPEUTICS INC. <br><br> They significantly reduced their stock positions in 10X GENOMICS INC (TXG) and ERASCA INC (ERAS). ARCH Venture Management, LLC opened new stock positions in GENERATE BIOMEDICINES INC. The fund showed a lot of confidence in some stocks as they added substantially to LYELL IMMUNOPHARMA INC (LYEL).

ARCH VENTURE CORP Equity Portfolio Value

Last Reported on: 15 May, 2026

$677Million

as of May 15, 2026

ARCH VENTURE CORP Annual Return Estimates Vs S&P 500

Our best estimate is that ARCH Venture Management, LLC made a return of 5.51% in the last quarter. In trailing 12 months, it's portfolio return was 142.46%.

Performance
S&P 500

New Buys

Ticker	$ Bought
generate biomedicines inc	24,305,300

New stocks bought by ARCH VENTURE CORP

Additions

Ticker	% Inc.
lyell immunopharma inc	17.69

Additions to existing portfolio by ARCH VENTURE CORP

Reductions

Ticker	% Reduced
10x genomics inc	-70.46
erasca inc	-35.86

ARCH VENTURE CORP reduced stake in above stock

Sold off

None of the stocks were completely sold off by ARCH VENTURE CORP

Sector Distribution

ARCH Venture Management, LLC has about 60.7% of it's holdings in Healthcare sector.

Healthcare
Others

Sector	%
Healthcare	60.7
Others	39.3

Market Cap. Distribution

ARCH Venture Management, LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.

UNALLOCATED
MID-CAP
SMALL-CAP

Category	%
UNALLOCATED	39.3
MID-CAP	33.6
SMALL-CAP	27.1

Stocks belong to which Index?

About 59.6% of the stocks held by ARCH Venture Management, LLC either belong to S&P 500 or RUSSELL 2000 index.

RUSSELL 2000
Others

Index	%
RUSSELL 2000	59.6
Others	40.4

Top 5 Winners (%)		%
ERAS	erasca inc	274.9 %
	q32 bio inc	93.4 %
VIR	vir biotechnology inc	48.6 %
TXG	10x genomics inc	19.5 %
	rapport therapeutics inc	3.1 %

Top 5 Winners ($)		$
ERAS	erasca inc	113.1 M
VIR	vir biotechnology inc	37.8 M
	rapport therapeutics inc	3.5 M
TXG	10x genomics inc	2.4 M
	q32 bio inc	1.0 M

Top 5 Losers (%)		%
GOSS	gossamer bio inc	-89.4 %
LYEL	lyell immunopharma inc	-33.1 %
	maze therapeutics inc	-27.9 %
BEAM	beam therapeutics inc	-14.0 %

Top 5 Losers ($)		$
	maze therapeutics inc	-47.7 M
LYEL	lyell immunopharma inc	-32.2 M
GOSS	gossamer bio inc	-22.3 M
BEAM	beam therapeutics inc	-17.7 M

ARCH VENTURE CORP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of ARCH VENTURE CORP

ARCH Venture Management, LLC has 10 stocks in it's portfolio. proved to be the most loss making stock for the portfolio. ERAS was the most profitable stock for ARCH Venture Management, LLC last quarter.

$677.09MTotal Value

10.00Positions

15 May, 2026Last Reported

Current holdings of Current Stock Holdings of ARCH VENTURE CORP, last reported on 15 May, 2026. Select a row with a linked ticker to view its historical trend.
Holdingsorted ascending	% Portfolio	Shares Held	$ Value	% Change
BEAM Beam Therapeutics Inc Beam Therapeutics IncBEAM ARCH VENTURE CORP's holding in Beam Therapeutics Inc over time	15.98%	4,540,130	$108.19M 15.98%	unchanged 0 percentunchanged

ERAS Erasca Inc Erasca IncERAS ARCH VENTURE CORP's holding in Erasca Inc over time	16.95%	7,091,560	$114.74M 16.95%	decreased 35.86 percentreduced

GOSS Gossamer Bio Inc Gossamer Bio IncGOSS ARCH VENTURE CORP's holding in Gossamer Bio Inc over time	0.39%	8,055,920	$2.65M 0.39%	unchanged 0 percentunchanged

LYEL Lyell Immunopharma Inc Lyell Immunopharma IncLYEL ARCH VENTURE CORP's holding in Lyell Immunopharma Inc over time	9.62%	3,247,160	$65.14M 9.62%	increased 17.69 percentadded

TXG 10x Genomics Inc 10x Genomics IncTXG ARCH VENTURE CORP's holding in 10x Genomics Inc over time	0.68%	217,834	$4.62M 0.68%	decreased 70.46 percentreduced

VIR Vir Biotechnology Inc Vir Biotechnology IncVIR ARCH VENTURE CORP's holding in Vir Biotechnology Inc over time	17.09%	12,916,700	$115.73M 17.09%	unchanged 0 percentunchanged

Com Maze Therapeutics Inc Maze Therapeutics Inc ARCH VENTURE CORP's holding in Maze Therapeutics Inc over time	18.16%	4,120,050	$122.98M 18.16%	unchanged 0 percentunchanged

Com Rapport Therapeutics Inc Rapport Therapeutics Inc ARCH VENTURE CORP's holding in Rapport Therapeutics Inc over time	17.23%	3,728,740	$116.67M 17.23%	unchanged 0 percentunchanged

Com Shs Generate Biomedicines Inc Generate Biomedicines Inc ARCH VENTURE CORP's holding in Generate Biomedicines Inc over time	3.59%	1,944,430	$24.31M 3.59%	new position

Com Q32 Bio Inc Q32 Bio Inc ARCH VENTURE CORP's holding in Q32 Bio Inc over time	0.3%	320,482	$2.06M 0.3%	unchanged 0 percentunchanged